help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
First published online on January 4, 2005
This version published online on July 14, 2005
Endocrine Reviews, doi:10.1210/er.2003-0037
Endocrine Reviews, doi:10.1210/er.2003-0037
Endocrine Reviews 0 (2005): 200300372-
Copyright © 2005 by The Endocrine Society
This Article
Right arrow Final Manuscript (PDF)
Right arrow All Versions of this Article:
26/5/615    most recent
Final Manuscript
Author Manuscript
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marx, S. J.
Right arrow Articles by Simonds, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marx, S. J.
Right arrow Articles by Simonds, W. F.

Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes

Stephen J. Marx* and William F. Simonds

Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1802

* To whom correspondence should be addressed. E-mail: StephenM{at}intra.niddk.nih.gov.

Hereditary origin of a tumor helps toward early discovery of its mutated gene; for example, it supports the compilation of a DNA panel from index cases to identify that gene by finding mutations in it. The gene for a hereditary tumor may contribute also to common tumors. For some syndromes, such as hereditary paraganglioma, several genes can cause a similar syndrome. For other syndromes, such as multiple endocrine neoplasia 2, one gene supports variants of a syndrome. Onset usually begins earlier and in more locations with hereditary than sporadic tumors. Mono- or oligoclonal ("clonal") tumor usually implies a postnatal delay, albeit less delay than for sporadic tumor, to onset and potential for cancer. Hormone excess from a polyclonal tissue shows onset at birth and no benefit from subtotal ablation of the secreting organ. Genes can cause neoplasms through stepwise loss of function, gain of function, or combinations of these. Polyclonal hormonal excess reflects abnormal gene dosage or effect, such as activation or haploinsufficiency. Polyclonal hyperplasia can cause the main endpoint of clinical expression in some syndromes or can be a precursor to clonal progression in others. Gene discovery is usually the first step toward clarifying the molecule and pathway mutated in a syndrome. Most mutated pathways in hormone excess states are only partly understood. The bases for tissue specificity of hormone excess syndromes are usually uncertain. In a few syndromes, tissue selectivity arises from mutation in the open reading frame of a regulatory gene (CASR, TSHR) with selective expression driven by its promoter. Polyclonal excess of a hormone is usually from a defect in the sensor system for an extracellular ligand (e.g., calcium, glucose, TSH). The final connections of any of these polyclonal or clonal pathways to hormone secretion have not been identified. In many cases, monoclonal proliferation causes hormone excess, probably as a secondary consequence of accumulation of cells with coincidental hormone-secretory ability.




This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
N. Garbrecht, M. Anlauf, A. Schmitt, T. Henopp, B. Sipos, A. Raffel, C. F Eisenberger, W. T Knoefel, M. Pavel, C. Fottner, et al.
Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity
Endocr. Relat. Cancer, March 1, 2008; 15(1): 229 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Beckers and A. F Daly
The clinical, pathological, and genetic features of familial isolated pituitary adenomas
Eur. J. Endocrinol., October 1, 2007; 157(4): 371 - 382.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Barlier, J.-F. Vanbellinghen, A. F. Daly, M. Silvy, M.-L. Jaffrain-Rea, J. Trouillas, G. Tamagno, L. Cazabat, V. Bours, T. Brue, et al.
Mutations in the Aryl Hydrocarbon Receptor Interacting Protein Gene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1952 - 1955.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Perren, M. Anlauf, T. Henopp, T. Rudolph, A. Schmitt, A. Raffel, O. Gimm, E. Weihe, W. T. Knoefel, H. Dralle, et al.
Multiple Endocrine Neoplasia Type 1 (MEN1): Loss of One MEN1 Allele in Tumors and Monohormonal Endocrine Cell Clusters But Not in Islet Hyperplasia of the Pancreas
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1118 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. F. Daly, M.-L. Jaffrain-Rea, A. Ciccarelli, H. Valdes-Socin, V. Rohmer, G. Tamburrano, C. Borson-Chazot, B. Estour, E. Ciccarelli, T. Brue, et al.
Clinical Characterization of Familial Isolated Pituitary Adenomas
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3316 - 3323.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. J. Marx and W. F. Simonds
Imaging to detect early endocrine cancers.
J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2861 - 2863.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society